Novartis and Arrowhead Forge $2.2 Billion Alliance to Combat Parkinson's with RNAi Technology

Novartis partners with Arrowhead Pharmaceuticals for ARO-SNCA, an innovative RNAi therapy targeting alpha-synuclein for Parkinson's Disease. The deal includes a $200M upfront payment and up to $2B in potential milestones.